AML

Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose…

- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no…

There was bad news and good news in a phase III trial evaluating intensive…

<!-- Name:DistributionId Value:8837590 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8788771 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8750375 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

About 20% of acute myeloid leukemia (AML) harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. Within…

Before the turn of the century, intensive chemotherapy was the only therapy that could produce clinically meaningful responses in…

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagersTri-specific T-cell engager resulted in AML cell-specific cytotoxicity…

NEW ORLEANS -- Patients with relapsed or refractory acute myeloid leukemia (AML) achieved similar outcomes with allogeneic…